Vitamin D regulates the phenotype of human breast cancer cells

Authors

  • Natalia Pendás-Franco,

    1. Instituto de Investigaciones Biomédicas “Alberto Sols” Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid E-28029 Madrid, Spain.
      Fax: 34 91 585 4401
    Search for more papers by this author
  • José Manuel González-Sancho,

    1. Instituto de Investigaciones Biomédicas “Alberto Sols” Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid E-28029 Madrid, Spain.
      Fax: 34 91 585 4401
    Search for more papers by this author
  • Yajaira Suárez,

    1. Instituto de Investigaciones Biomédicas “Alberto Sols” Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid E-28029 Madrid, Spain.
      Fax: 34 91 585 4401
    Search for more papers by this author
  • Oscar Aguilera,

    1. Instituto de Investigaciones Biomédicas “Alberto Sols” Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid E-28029 Madrid, Spain.
      Fax: 34 91 585 4401
    Search for more papers by this author
  • Andreas Steinmeyer,

    1. Medical Chemistry III, Research Centre Europe, Shering AG, D-13342 Berlin, Germany
    Search for more papers by this author
  • Carlos Gamallo,

    1. Hospital Universitario de la Princesa, E-28006 Madrid, Spain
    Search for more papers by this author
  • María T. Berciano,

    1. Departamento de Anatomía y Biología Celular, Unidad de Biomedicina CSIC, Universidad de Cantabria, E-39011 Santander, Spain
    Search for more papers by this author
  • Miguel Lafarga,

    1. Departamento de Anatomía y Biología Celular, Unidad de Biomedicina CSIC, Universidad de Cantabria, E-39011 Santander, Spain
    Search for more papers by this author
  • Alberto Muñoz

    Corresponding author
    1. Instituto de Investigaciones Biomédicas “Alberto Sols” Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid E-28029 Madrid, Spain.
      Fax: 34 91 585 4401
      ✉ E-mail: amunoz@iib.uam.es
    Search for more papers by this author

✉ E-mail: amunoz@iib.uam.es

Abstract

Abstract 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3), the most active vitamin D metabolite, regulates proliferation, survival, and differentiation in many cell types. 1,25(OH)2D3 and several less calcemic analogs are in clinical trials against various neoplasias. We studied the effects of 1,25(OH)2D3 on a panel of human breast cancer cells, which show similar vitamin D receptor (VDR) content but variable transcriptional and anti-proliferative responsiveness. In MDA-MB-453 cells, one of the responsive lines, 1,25(OH)2D3 increased cell and nuclear size and induced a change from a rounded to a flattened morphology. By phase contrast, laser confocal and electron microscopy, we found that 1,25(OH)2D3 changed the cytoarchitecture of actin filaments and microtubules and nuclear shape, induced filopodia and lamellipodia, and promoted cell-to-cell contacts via large cytoplasmic extensions. However, although claudin-7 and occludin content in the cells increased upon exposure to 1,25(OH)2D3, these proteins were not located at the plasma membrane probably due to the absence of E-cadherin expression. Additionally, 1,25(OH)2D3 induced the accumulation of αv-integrin, β5-integrin, focal adhesion kinase (FAK), and paxillin in focal adhesion plaques, concomitant with the increased phosphorylation of the FAK. 1,25(OH)2D3 enhanced MDA-MB-453 and MDA-MB-468 cell adhesion to plastic but decreased adhesion to laminin. The expression of the mesenchymal marker N-cadherin and of the myoepithelial marker P-cadherin was down-regulated by 1,25(OH)2D3 in several breast cancer cell lines. Other myoepithelial proteins such as α6-integrin, β4-integrin, and smooth muscle α-actin (SMA) were also repressed by 1,25(OH)2D3 in MDA-MB-453 and MDA-MB-468 cells. Accordingly, mice lacking VDR (Vdr−/−) showed abnormally high levels of SMA and P-cadherin in their mammary gland. These findings show that 1,25(OH)2D3 profoundly affects the phenotype of breast cancer cells, and suggest that it reverts the myoepithelial features associated with more aggressive forms and poor prognosis in human breast cancer.

Ancillary